Noah Gottdiener and Thierry Porté join BOD; Joseph B. Kelley joins Business Advisory Board
One new drug may treat both Covid-19 and Alzheimer’s
The interview took place at the 2020 BIO CEO & Investor Conference
Jay Mohr, Chief Operating and Business Officer, will be providing a corporate update and participating on a late-stage CNS therapeutics panel.
Company will be providing a company overview and participating on a CNS panel
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS
Brings more than 20 years of experience in the life science industry to support pre-commercial and regulatory activities of Phase 3 candidate ALZT-OP1 for early Alzheimer’s disease
The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate and pipeline of candidates.
Cutting-edge CAR-Treg technology could have broad application across common and rare neurodegenerative diseases; Smith Founder and CEO Philip Ashton-Rickardt, Ph.D. joins as SVP of Immunology
Proceeds to support ongoing Phase 3 Alzheimer’s clinical trial, expected to complete in 2020, and advancement of pipeline of candidates targeting neuroinflammation